for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

AnGes Inc

4563.T

Latest Trade

1,540.00JPY

Change

--(--)

Today's Range

--

 - 

--

52 Week Range

375.00

 - 

2,492.00

As of on the Tokyo Stock Exchange ∙ Minimum 15 minute delay

Pricing

Previous Close
1,540.00
Open
--
Volume
--
3M AVG Volume
366.29
Today's High
--
Today's Low
--
52 Week High
2,492.00
52 Week Low
375.00
Shares Out (MIL)
122.99
Market Cap (MIL)
191,871.50
Forward P/E
--
Dividend (Yield %)
--

Next Event

Dividend For 4563.T - 0.0000 JPY

Latest Developments

More

AnGes says exercise of options

AnGes says exercise of options

AnGes says exercise of options

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About AnGes Inc

AnGes, Inc., formerly AnGes MG, Inc., is a Japan-based company mainly engaged in the development of genetic medicines. The Company is involved in the development of hepatocyte growth factor (HGF) genetic medicines, NF-KB decoy oligo and hemagglutinating virus of Japan envelope (HVJ-E) non-viral vector, among others. As of December 31, 2012, the Company had four consolidated subsidiaries. On January 31, 2013, the Company sold a 95.3% stake of a Osaka-based subsidiary to ISHIHARA SANGYO KAISHA LTD.

Industry

Biotechnology & Drugs

Contact Info

7-7-15 Saito-asagi

Saito Bio-Incubator 4 Fl.

IBARAKI-SHI, OSK

567-0085

Japan

+81.3.57302641

https://www.anges.co.jp/

Executive Leadership

Ei Yamada

President, Executive President, Chief Executive Officer of Subsidiaries, Representative Director

Tetsuharu Yoneo

Executive Officer, Director of Finance, Director

Kazuo Suzuki

Executive Officer, Director of Business Planning, Director of Drug Discovery Research, Director

Tetsuya Ishihama

Executive Officer, Director of Clinical Development, Director of Medicine

Makoto Seki

Executive Officer, Chief Director of Business Planning

Key Stats

Price To Earnings (TTM)
--
Price To Sales (TTM)
1,121.95
Price To Book (MRQ)
8.86
Price To Cash Flow (TTM)
--
Total Debt To Equity (MRQ)
--
LT Debt To Equity (MRQ)
--
Return on Investment (TTM)
-20.76
Return on Equity (TTM)
-20.39

Latest News

Latest News

Japan's AnGes speeds towards 2021 rollout in coronavirus 'vaccine war'

Japanese biotech AnGes Inc expects its coronavirus vaccine to be ready as early as the first half of 2021, if it can overcome supply chain and production hurdles, the company's founder said.

Pharma firm Anges and Osaka University to begin testing coronavirus vaccine on animals

Japanese biopharmaceutical firm Anges Inc said on Tuesday that it and Osaka University had completed development of a DNA vaccine against the new coronavirus and that it would begin testing it in animals soon.

Pharma firm Anges and Osaka University to begin testing coronavirus vaccine on animals

Japanese biopharmaceutical firm Anges Inc said on Tuesday it and partner Osaka University had completed development of a prophylactic DNA vaccine against the new coronavirus and that it would begin testing it in animals soon.

Anges to develop coronavirus vaccine with Osaka University

Japanese biopharmaceutical firm Anges inc said on Thursday it would join hands with Osaka University to develop a coronavirus vaccine.

BRIEF-AnGes submits application for marketing approval for HGF gene therapy

* Says it submits application for marketing approval to Pharmaceuticals and Medical Devices Agency (PMDA) for HGF gene therapy for the treatment of critical limb ischemia (CLI)

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up